Mohammad Azab's Net Worth
$2.93 Million
Who is Mohammad Azab?
Mohammad Azab has an estimated net worth of $2.93 Million. This is based on reported shares across multiple companies, which include Xenon Pharmaceuticals Inc., DURECT CORP, QLT INC/BC, LISATA THERAPEUTICS, INC., Astex Pharmaceuticals, Inc, and CHEMOKINE THERAPEUTICS CORP.
SEC CIK
Mohammad Azab's CIK is 0001309653
Past Insider Trading and Trends
2022 was Mohammad Azab's most active year for acquiring shares with 13 total transactions. Mohammad Azab's most active month to acquire stocks was the month of April. 2013 was Mohammad Azab's most active year for disposing of shares, totalling 6 transactions. Mohammad Azab's most active month to dispose stocks was the month of September. 2022 saw Mohammad Azab paying a total of $152,081.99 for 155,286 shares, this is the most they've acquired in one year. In 2013 Mohammad Azab cashed out on 1,108,753 shares for a total of $0.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Xenon Pharmaceuticals Inc. (XENE) Snapshot price: $38.47
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +6.18% | 4.32K |
$9.85 | $42,552.00 | 74.22K |
Dec 19
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 2
| |||
Form 4
| +4.62% | 3.09K |
$2.68 | $8,270.48 | 69.91K |
Dec 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 28
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
DURECT CORP (DRRX) Snapshot price: $1.5699
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 21
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 15
| |||
Form 4
| +100.00% | 30K |
$0.39 | $11,638.00 | 60K |
May 24
| |||
Form 4
|
∞
| 30K |
$0.41 | $12,173.51 | 30K |
May 16 - May 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 4
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
QLT INC/BC No price found
Exec VP-R&D, CMO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +500.00% | 1K |
$10.28 | $10,275.90 | 1.2K |
May 24
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 9
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
LISATA THERAPEUTICS, INC. (LSTA) Snapshot price: $3.13
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +49.69% | 19.48K |
—
|
—
| 58.68K |
Jan 9
| |||
Form 4
| +104.17% | 20K |
—
|
—
| 39.2K |
Jan 9
| |||
Form 4
|
∞
| 19.2K |
$6.25 | $120,000.00 | 19.2K |
Sep 15
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Astex Pharmaceuticals, Inc No price found
Chief Medical Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -8.75K |
—
|
—
|
0
|
Oct 11
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 24
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 11
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 21
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||